DIRS.INFO The most relevant business & tech news

☆ Keep buying this GLP-1 juggernaut that's already up nearly 50% this year, TD Cowen says
▼ + stars: | 2023-12-04 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

Novo Nordisk is blessed with an extremely promising growth outlook, according to TD Cowen. NVO YTD mountain Novo Nordisk YTD chart Novo Nordisk is one of the largest makers of glucagon-like peptide 1 drugs used to treat both diabetes and obesity. "The company's merits have been widely recognized, and its shares have outperformed, but we believe there is more gas in the tank," the TD Cowen analyst wrote. For one, the analyst expects Novo's strong revenue and earnings growth to outpace its peers, especially as the company benefits from global GLP-1 supply constraints. "We are optimistic for favorable outcomes on all fronts," the analyst wrote.

Persons: TD Cowen, Michael Nedelcovych's, Cowen, Nedelcovych, Novo's, NASH, — CNBC's Michael Bloom Organizations: Novo Nordisk, Nordisk, Novo, European Union Locations: Danish, Novo

☆ Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops
▼ + stars: | 2023-12-02 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

That includes Novo Nordisk 's Wegovy and diabetes treatment Ozempic as well as Eli Lilly 's diabetes drug Mounjaro. They have all skyrocketed in popularity — and slipped into shortages — over the last year for safely and successfully causing significant weight loss. But before the current weight loss industry gold rush, the path to treating obesity was strewn with failures dating back decades. In its full-year 2019 earnings, Eisai reported that Lorcaserin had sales of $28.1 million in the U.S. for the year. Sanofi's rimonabantAn obesity drug called rimonabant from Sanofi and Aventis was withdrawn from all markets in 2008 due to the risk of serious psychiatric problems, including suicide.

Persons: Eli Lilly, drugmakers, lorcaserin, Eisai, Lorcaserin Organizations: Getty, Pfizer, Novo Nordisk, U.S, Drug Administration, FDA, Aventis, Abbott Laboratories Locations: U.S, Sanofi

☆ A dietitian and health professor shares the 2 supplements she recommends for improving heart health
▼ + stars: | 2023-12-02 | by ( Kim Schewitz | ) www.businessinsider.com time to read: +4 min

AdvertisementA dietitian shared the two supplements she recommends for lowering cholesterol levels and improving heart health. When thinking about supplements for heart health, cholesterol is typically the target, Lauren Ball, a dietitian and professor of community health and wellbeing at the University of Queensland, Australia, told Business Insider. AdvertisementOne meta-analysis of eight clinical trials published in 2000 found that taking 10g psyllium husk daily appeared to lower total cholesterol levels by 4% and LDL cholesterol levels by 7%. Similarly to fiber supplements, they are thought to work by improving the body's ability to pass stools. You are also less likely to experience side effects such as constipation from probiotics than from fiber supplements, she said.

Persons: —, Lauren Ball, Ball, Probiotics, probiotics Organizations: Service, University of Queensland, FDA Locations: Australia

☆ US obesity docs expect Lilly weight-loss drug to show similar heart benefit as Wegovy
▼ + stars: | 2023-12-01 | by ( Patrick Wingrove | ) www.reuters.com time to read: +5 min

REUTERS/Mike Segar Acquire Licensing RightsDec 1 (Reuters) - Some leading U.S. obesity specialists say they expect Eli Lilly’s (LLY.N) powerful weight-loss drug Zepbound will produce the same or similar heart benefits as Novo Nordisk’s (NOVOb.CO) popular Wegovy as they belong to the same class of medicines. In Novo's pivotal Wegovy trial involving 17,604 overweight and obese people without diabetes, the drug reduced incidence of heart attack, stroke or heart-related death by an impressive 20%. The product, which has the same active ingredient - tirzepatide - as its previously approved diabetes drug Mounjaro, is expected to start shipping it before the end of the year. They said they would readily prescribe Wegovy (semaglutide) if their patients' insurance did not cover Lilly’s drug, or if future trial results do not produce similar heart benefits. Lilly declined to comment on doctors' views that Zepbound might have the same or similar cardiovascular benefits as Wegovy.

Persons: Eli Lilly, Mike Segar, Eli Lilly’s, Lilly, Danish drugmaker, Edmond Wickham, Emily, Zepbound, Tirzepatide, ”, Rohit Kedia, Novo, Chad Weldy, semaglutide, tirzepatide, Farxiga, Boehringer Ingelheim, Lilly’s Jardiance, Patrick Wingrove, Caroline Humer, Bill Berkrot Organizations: Company, REUTERS, Novo, Wegovy, Virginia Commonwealth University . The, Virginia Commonwealth University . The U.S . Food, Drug Administration, Wall Street, Barclays, Providence, Stanford University, Thomson Locations: Branchburg , New Jersey, Danish, Virginia Commonwealth University . The U.S, Zepbound, U.S

☆ Competition will make obesity drugs successful
▼ + stars: | 2023-12-01 | by ( Robert Cyran | ) www.reuters.com time to read: +3 min

In an interview with the Financial Times, he proposed spreading reimbursements over time if the medication proves to be successful. There’s some practical grounding in that solution, but the path of other similar drugs suggests that a competitive market is a better way to make it successful. Snag is, the drugs cost several thousand dollars per patient annually, even after discounts. Medicare, which covers 66 million seniors, can’t pay for weight loss drugs under current law. While it makes more sense for insurers or governments to pay over time if the drugs benefits last, schemes like the one that Jørgensen suggests can only do so much.

Persons: Lars Fruergaard Jørgensen, Jørgensen, “, Lauren Silva Laughlin, Sharon Lam Organizations: Reuters, Novo Nordisk, Financial Times, Centers for Disease Control, Prevention, North Carolina, The New England, of Medicine, Employers, Thomson Locations: U.S, The, United States, Danish

☆ One identical twin went vegan while the other didn’t. See what happened
▼ + stars: | 2023-11-30 | by ( Sandee Lamotte | ) edition.cnn.com time to read: +7 min

A vegan diet differs from a vegetarian diet in that it eliminates not only animal flesh but dairy, eggs or any other ingredient derived from animals. In each pair, one twin was assigned a vegan diet, while the other was assigned an omnivore diet. “I feel like a lot of people who do a vegan diet think ‘Oh great, soda is vegan. Cutting back on eating meat and animal byproducts can be done slowly, bit by bit. Harvard’s Hu agreed: “While this study showed a vegan diet may provide additional advantages compared to a healthy omnivorous diet, it does not mean that everyone should become a vegan or vegetarian.

Persons: ”, Christopher Gardner, Gardner, “, ” Alice Lichtenstein, Frank Hu, ” Hu, ” Gardner, “ I’m, quinoa, there’s, Harvard’s Hu Organizations: CNN, Stanford Prevention Research Center, Nutrition Studies Research, Stanford, Tufts University’s Cardiovascular Nutrition Laboratory, Harvard, of Public Health, JAMA Locations: Palo Alto , California, Chan, Boston, Brussels, Yukon

☆ How to reduce your risk of cancer: 7 lifestyle recommendations from scientists
▼ + stars: | 2023-11-29 | by ( Serafina Kenny | ) www.businessinsider.com time to read: +5 min

People who most closely followed seven recommendations appeared to have a lower cancer risk. The study's authors acknowledge that their study is observational, and so doesn't prove following the recommendations lower the risk of cancer. More research is needed to investigate the specific impacts of each of lifestyle factor on cancer risk. They also recommend not smoking and avoiding excess sun to reduce cancer risk. AdvertisementMalcomson said: "People should aim to follow as many of the Cancer Prevention Recommendations as they can to reduce their risk of cancer and other non-communicable diseases.

Persons: —, Fiona Malcomson, Malcomson Organizations: Service, BMC Medicine, World Cancer Research Fund, American Institute for Cancer Research, Newcastle University, UK, BMI, Nutrition Research, Cancer Locations: England, Wales, Scotland, Newcastle

☆ 4 diet changes that may help ADHD symptoms, according to a dietitian
▼ + stars: | 2023-11-28 | by ( Julia Pugachevsky | ) www.businessinsider.com time to read: +4 min

ADHD symptoms can include forgetfulness, hyperactivity, and impulsiveness. AdvertisementIf you have ADHD symptoms such as forgetfulness or hyperactivity, there are some simple hacks you can try to alleviate them. Gala Didebashvili/Getty ImagesBefore trying any supplements, Holwegner strongly emphasized making sure that anyone with ADHD is eating enough protein. (Some research has linked sugary foods to an increase in ADHD symptoms in kids, but so far the science is mixed .) Incorporate omega-3Getty ImagesOmega-3 fatty acids have been linked to improved ADHD symptoms in children, and there are several ways to incorporate them into a diet.

Persons: —, Andrea Holwegner, I'm, Holwegner, Didebashvili, it's Organizations: Service, Health, Nutrition Consulting, Amazon

☆ This biotech stock targeting genetically driven diseases could nearly double, predicts JPMorgan
▼ + stars: | 2023-11-28 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +3 min

Lexeo Therapeutics ' stock could nearly double as its gene therapies advance through its pipeline, according to JPMorgan. That implies a potential upside of nearly 82% from the stock's Monday closing price of $11. LXEO ALL mountain Lexeo Therapeutics all-time stock chart Analyst Tessa Romero cited Lexeo Therapeutics' lead cardiac therapy, LX2006, as a catalyst for the stock. The gene therapy is delivered to body tissues through an adeno-associated virus vector and it targets a rare genetic heart disorder called Friedreich's ataxia cardiomyopathy. The firm is also evaluating a similar type of gene therapy, LX2020, to treat cases of PKP2-ACM, another kind of inherited heart disease.

Persons: Tessa Romero, Lexeo, Romero, LX2020, LX1001, – LX2006, Michael Bloom Organizations: Therapeutics, JPMorgan, Lexeo Therapeutics, ACM, ~$ Locations: U.S

☆ Virginia's 'Data Center Alley' residents say an eerie hum is keeping them up at night
▼ + stars: | 2023-11-27 | by ( Rosalie Chan | ) www.businessinsider.com time to read: +9 min

At the beginning of this year, she started hearing an eerie hum that got louder at night. Virginia has had explosive growth in data centers since the early 2000s, when Loudoun County started allowing data centers to be built. Loudoun County residents say the noise started this past winter and gets louder at night when it's cooler. In Loudoun County, residents said they could hear the data center even with their windows closed. Unlike previous data centers, the new ones use so-called free air cooling , designed to leverage lower temperatures to use less electricity than most data centers.

Persons: Stephanie Brookes, Brookes, Les Blomberg, he's, Mike Turner, Ted Lewis, Turner, Eric Lee, Jeff Mach, Mach, Katy Hancock, Hancock, Chris Crosby, Blomberg, it's, Lewis, Arline Bronzaft, Wire Blomberg Organizations: Business, Compass, Pollution, The Washington Post, county's, Supervisors, Loudoun County's, Public, Lehman College Locations: Loudoun County , Virginia, Virginia, Loudoun County, Leesburg, New York, Ashburn, Loudoun, Loudoun County's

Women going through menopause raise concerns about weight and body changes almost as often as they do about hot flashes and night sweats, said Dr. Stephanie Faubion, medical director for the Menopause Society and a director of the Mayo Clinic’s Center for Women’s Health. Some estimates suggest that roughly 70 percent of women gain up to 1.5 pounds per year during the menopause transition, which can last as long as a decade. This weight gain can affect women’s self-esteem and quality of life and can also increase the risk of diabetes, cardiovascular disease and other health issues. Excess weight is also correlated with more hot flashes and night sweats; the Menopause Society recommends weight loss as an effective nonhormonal treatment for those symptoms. Now, some women going through menopause are seeking drugs like Ozempic, despite the steep costs: Without insurance coverage, the drugs can run around $1,000 a month.

Persons: sweats, Stephanie Faubion, “, they’re, ”, “ We’re, Faubion, Daniela Hurtado Organizations: Mayo Clinic’s Center, Women’s Health, Mayo Clinic Locations: United States

☆ Practicing gratitude: Turns out sometimes less is more, expert says
▼ + stars: | 2023-11-26 | by ( Faye Chiu | Jessica Dulong | ) edition.cnn.com time to read: +9 min

You don’t have to look far to find countless recommendations for a gratitude practice as a key to happiness. For people who like to write, an effective gratitude practice could be writing thank-you notes to friends and family, Lyubomrisky said. Lyubomirsky: There are circumstances in which a gratitude practice can backfire. How to get help Help is available if you or someone you know is struggling with suicidal thoughts or mental health matters. CNN: What advice do you have for avoiding pitfalls while engaging in a gratitude practice?

Persons: Sonja Lyubomirsky, “, you’re, Lyubomrisky, towfiqu, Jessica DuLong, ” Organizations: CNN, University of California, Getty, International Association for Suicide Prevention, Befrienders Locations: Riverside, Santa Monica, Canada, Brooklyn , New York

☆ So many kids are falling sick in China that a children's hospital said it saw 13,000 cases in a single day
▼ + stars: | 2023-11-23 | by ( Matthew Loh | Kim Schewitz | ) www.businessinsider.com time to read: +6 min

Northern China is struggling with a wave of respiratory illnesses among its children. Cities like Beijing and Tianjin have been hit hard by cases of flu and pneumonia, hospitals said. Children wait on the stairs at a children hospital in Beijing on November 23, 2023, with some administered with drips. "All the children have respiratory illnesses." Children receive a drip at a children hospital in Beijing on November 23, 2023.

Persons: —, Liu Wei, Liu, imploring, JADE GAO, Mi Feng, they're, It's, JADE GAOJADE, Hu Xijin, Hu, David Heymann, Francois Balloux Organizations: Service, Beijing Aviation General, Management, drips, Getty, Changjiang, Health, Business, Global Times, Health Organization, London School of Hygiene, Tropical Medicine, UCL Genetics Institute Locations: Northern China, Cities, Beijing, Tianjin, China, Tianjian, Wuhan, Hubei, Chongqing, Weibo

☆ People taking ADHD medications should closely monitor their heart health, study suggests
▼ + stars: | 2023-11-22 | by ( Deidre Mcphillips | ) edition.cnn.com time to read: +5 min

CNN —Long-term use of ADHD medications can raise the risk of cardiovascular disease in both children and adults, according to a study published Wednesday in JAMA Psychiatry. The researchers found that people taking ADHD medications had a higher risk of hypertension and arterial disease, and the risk increased over time. Careful attention to the heart health of patients with ADHD is not new, experts say. “I don’t want to minimize this,” he said, highlighting the importance of screening for heart health in ADHD patients before starting treatment and checking in regularly. The risk for cardiovascular disease may be underestimated in the new study, the researchers wrote, as some heart disease that does not yet require medical care may not be diagnosed.

Persons: CNN —, Mitch Elkind, there’s, “, ”, David Goodman, ” Goodman, ‘, ” Elkind, Dr, Sanjay Gupta Organizations: CNN, Psychiatry, American Heart Association . Children, US Centers for Disease Control, Johns Hopkins School of Medicine, American Professional Society, CNN Health Locations: Sweden

REUTERS/George Frey/File Photo Acquire Licensing RightsNov 21 (Reuters) - Tema ETFs has launched a new exchange traded fund (ETF) that tracks popular drugmakers like Novo Nordisk (NOVOb.CO) and Eli Lilly (LLY.N), aiming to tap into growing demand for their weight-loss and diabetes drugs. The Tema Cardiovascular & Metabolic ETF (HRTS.O) invests in companies tackling diabetes, obesity and cardiovascular diseases, according to the New York-headquartered platform's website. The advances of the class of weight-loss and diabetes therapies known as GLP-1 receptor agonists, are only the tip of the iceberg, said David K. Song, investment partner and head of life sciences at Tema ETFs. The Tema fund has a net expense ratio of 0.75%. Reporting by Bansari Mayur Kamdar in Bengaluru; Editing by Emelia Sithole-MatariseOur Standards: The Thomson Reuters Trust Principles.

Persons: Lilly, George Frey, Eli Lilly, Mounjaro, David K, Morgan Stanley, Bansari Mayur, Emelia Sithole Organizations: Novo Nordisk, Pharmacy, REUTERS, Metabolic, Morgan Stanley Research, VanEck Pharmaceutical, Thomson Locations: Provo , Utah, U.S, Tema, Novo, New York, Bengaluru

☆ Eating plant-based foods instead of meat may cut diabetes and heart disease risk
▼ + stars: | 2023-11-20 | by ( Issy Ronald | ) edition.cnn.com time to read: +6 min

CNN —Replacing animal-based food such as red and processed meat or eggs with plant-based options such as nuts or legumes may reduce the risk of developing heart disease and type 2 diabetes, a comprehensive review has found. Previous studies have already indicated some health benefits from plant-based diets. Simply switching animal-based products for plant-based products doesn’t automatically result in a healthy diet. “We need to be cautious about words like plant-based, which can be used by food manufacturers,” Mellor said. “Just because the statistics say a swap reduces risk, does it make culinary and cultural sense?

Persons: ” Sabrina Schlesinger, Schlesinger, Duane Mellor, ”, Mellor, wasn’t, ” Mellor, “ Organizations: CNN, BMC Medicine, German Diabetes Center, Aston Medical School, World Health Organization, US Department of Agriculture Locations: Düsseldorf, Birmingham, UK

☆ OpenAI Upheaval in Focus, Microsoft Stock Edges Higher: Stock Market News Today
▼ + stars: | 2023-11-20 | by ( ) www.wsj.com time to read: +1 min

Microsoft stock was gaining after the software giant said Sam Altman—OpenAI's fired chief executive—would lead its new advanced AI research team . Now more than 500 OpenAI employees have threatened to leave the company if the current board doesn't resign and reinstate Altman. The chip maker’s stock—which has been a big contributor to the S&P 500's gains this year—was also higher in recent trading. All three major stock indexes are coming off their third straight weekly advance, including a 2.2% gain for the S&P 500. Benchmarks in Asia mostly rose, with consumer and tech stocks helping push Hong Kong’s Hang Seng Index up 1.9%.

Persons: Sam Altman — OpenAI's, —, Altman, Javier Milei Organizations: Microsoft, Nvidia, Nasdaq, Bayer, Bristol Myers Squibb, U.S, Treasury, greenback, Global Locations: OpenAI, U.S, Europe, Asia

☆ Obesity Drugs Put These Stocks on a Crash Diet—Now They’re Rebounding
▼ + stars: | 2023-11-17 | by ( David Wainer | ) www.wsj.com time to read: 1 min

Makers of medical devices were prepared for doom and gloom following a study of obesity drugs and cardiovascular health—but the bearish scenario hasn’t panned out. Photo: Catherine Ivill/Getty ImagesThere is a bit of cognitive dissonance in healthcare investing right now. After reviewing the highly anticipated results from a study of Novo Nordisk’s blockbuster obesity treatment Wegovy released over the weekend, cardiologists at a major medical meeting and the pharma crowd on Wall Street were broadly upbeat. “Today’s confirmatory results lay the groundwork for the coming paradigm shift of metabolic treatment,” gushed Evan Seigerman, an analyst at BMO Capital Markets.

Persons: Catherine Ivill, Novo, Wegovy, ” gushed Evan Seigerman Organizations: pharma, BMO Capital Markets

☆ Some healthcare systems are taking on the challenge of health inequity — but ending the disparities isn't a quick process
▼ + stars: | 2023-11-17 | by ( Heather Lindsey | ) www.businessinsider.com time to read: +7 min

Some health systems are embedding health-equity programs in their business strategies. The report said health inequities led to increased costs associated with premature death, loss of work productivity, and excess medical spending. "When you lean into health equity, you can create value, better outcomes, and lower costs," he said. Bhatt said health systems can push for health equity by creating diverse care teams. "If you lean into health equity," Bhatt said, "there is opportunity to improve outcomes, build consumer loyalty and trust, and create economic value."

Persons: —, Keneica Moore, Moore, MAAME doulas, Sarahn Wheeler, Wheeler, who's, inequity, Jay Bhatt, Bhatt Organizations: Healthcare, Service, Empowerment, Duke Health, Centers for Disease Control, National Institute, Minority Health, Deloitte Health Equity Institute, Deloitte Center for Health Solutions Locations: Durham, North Carolina

☆ For Health, More Nuts, Beans and Whole Grains
▼ + stars: | 2023-11-15 | by ( Alice Callahan | ) www.nytimes.com time to read: +2 min

The case has never been clearer: Eat less bacon and more beans. Chan School of Public Health, who was not involved with the study. Researchers followed them for an average of 19 years and looked for correlations between their diets and health. They adjusted for other factors that can affect health, including calorie intake, physical activity, smoking and alcohol use. But the findings were consistent between studies, she said, and are supported by other research that points in the same direction.

Persons: Qi Sun, Sabrina Schlesinger Organizations: BMC Medicine, Harvard, of Public Health, German Diabetes Center Locations: Chan, United States, Europe, Asia, Düsseldorf, Germany

☆ The Trouble With America’s Ultra-Processed Diet
▼ + stars: | 2023-11-14 | by ( Andrea Petersen | ) www.wsj.com time to read: 1 min

Should your granola bar come with a warning label? Concern is rising about the amount of ultra-processed foods in American diets, and the effect eating so many of those foods has on our health. Part of the problem, nutrition researchers say, is that lots of healthy-seeming items—many breakfast cereals, soups and yogurts as well as granola—fall into that category. Recent studies have linked diets high in ultra-processed foods to increased risks of obesity, Type 2 diabetes, cancer, cardiovascular disease and depression.

☆ Medical device stocks rise in relief after Wegovy heart benefits data
▼ + stars: | 2023-11-13 | by ( ) www.reuters.com time to read: +2 min

A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. To be sure, the full results presented on Saturday at a major medical meeting gave analysts even more confidence in the heart protective benefits of the hugely popular drug. That lifted shares of Penumbra (PEN.N), which makes devices used in surgeries for stroke patients, 13% in morning trading. Its shares have tumbled about 28% as of last close since Novo in August said Wegovy had also shown a clear cardiovascular benefit. "The full detailed results ... do not shift our outlook that MedTech device stocks appear broadly oversold," said Leerink analyst Mike Kratky.

Persons: Victoria Klesty, Wegovy, Baird, Jeff Johnson, Eli Lilly's, Mike Kratky, Leroy Leo, Medha Singh, Sriraj Organizations: REUTERS, Novo, Devices, Abbott Laboratories, Thomson Locations: Oslo, Norway, Victoria, MedTech, Penumbra, Novo, Friday's, Bengaluru

☆ Novo Nordisk shares rise as Wegovy shows heart benefits beyond weight loss
▼ + stars: | 2023-11-13 | by ( Maggie Fick | ) www.reuters.com time to read: +3 min

LONDON, Nov 13 (Reuters) - Novo Nordisk (NOVOb.CO) shares rose 3% on Monday as the market reacted to data the drugmaker presented over the weekend showing that the heart protective benefits of its popular obesity drug Wegovy are not solely due to weight loss. Wegovy is part of a class of drugs that mimic a gut hormone that helps regulate blood sugar and appetite. U.S. companies across sectors such as food and beverage makers have addressed investor concerns on the potential impact to their businesses from the growing popularity of the promising weight-loss drugs. Novo was first to market with its highly effective weight loss drugs. At the close of markets on Friday, Novo's shares were up 47.5% this year.

Persons: Markus Manns, Jefferies, Wegovy, Novo, Eli Lilly's, Lilly, Novo's, Maggie Fick, Boleslaw Lasocki, Medha Singh, Louise Heavens Organizations: Novo Nordisk, Novo, Union Investment, Reuters, Pfizer, Jefferies, U.S, Thomson Locations: United, Germany, Novo, U.S, Bengaluru

☆ Jim Cramer says insurance companies will pay for 'revolutionary' weight-loss drugs for their members
▼ + stars: | 2023-11-13 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

CNBC's Jim Cramer on Monday emphasized his belief that GLP-1 drugs primarily used to treat diabetes and obesity and the companies that make them, like Eli Lilly and Novo Nordisk , will be very valuable. And for millions of people, it'll be cheaper for the insurance companies to shell out for the new weight-loss drugs than to let their morbidly obese members just get heart disease," he said. Cramer called these drugs "revolutionary," citing new data from Novo Nordisk suggesting its drug Wegovy cut the risk of serious cardiovascular complications in patients with obesity and heart disease by 20%. For example, type two diabetes can put patients at risk for other health issues, so insurance companies would want to pay for the drugs in order to prevent further complications, he said. Similarly, those with obesity and treatment-resistant high blood pressure are at higher risk for heart disease, making them primary candidates for the drugs.

Persons: CNBC's Jim Cramer, Eli Lilly, Cramer Organizations: Novo Nordisk

Eight of the 11 major S&P 500 sectors were in the red, with rate-sensitive real estate stocks (.SPLRCR) down 1.2% and leading declines. This week's economic data as well as speeches from Fed officials will provide clues on the trajectory of interest rates amid growing expectations that the Fed is done hiking borrowing costs. The major U.S. stock indexes have rebounded strongly this month, fueled by a stronger-than-expected earnings season and on hopes that U.S. interest rates are near their peak. The benchmark S&P 500 (.SPX) closed at near eight-week highs on Friday, while the tech-heavy Nasdaq (.IXIC) hit a two-month peak. The S&P index recorded 11 new 52-week highs and one new low, while the Nasdaq recorded 19 new highs and 82 new lows.

Persons: Brendan McDermid, Peter Cardillo, Cardillo, Mike Johnson, Abbott, advancers, Sruthi Shankar, Amruta, Maju Samuel Organizations: New York Stock Exchange, REUTERS, Boeing, Dow, Nasdaq, Federal Reserve, Treasury, Microsoft, Apple, Spartan Capital Securities, . House, Republican, Dow Jones, Novo Nordisk's, Bloomberg News, Max, NYSE, Thomson Locations: New York City, U.S, China, Bengaluru

Search resuls for: "Cardiovascular"

25 mentions found